Clinical Trial Update: A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

View source ↗

Summary

Pfizer-sponsored post-marketing surveillance study for renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Status: WITHDRAWN